Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Approved · ActiveModality: regenerative medicine (bioengineered vessel)
Aliases acellular tissue engineered vessel, ATEV
Partnerships Fresenius Medical Care (agreement to sell, market and distribute 6mm ATEV for specified indications and markets, if approved); Kingdom of Saudi Arabia (commitment to purchase Symvess for clinical evaluation and outreach program)
Indications
extremity vascular trauma(Approved)
Status note Commercial product. ATEV assigned a priority designation by the Secretary of Defense under Public Law 115-92 (2018) to expedite FDA review for conditions facing military personnel.
ATEV (AV access program)
Phase 3 · ActiveModality: regenerative medicine (bioengineered vessel)
Indications
arteriovenous access for hemodialysis(Phase 3)
Catalysts
— H2 2026
Status note Ongoing V007 and V012 Phase 3 trials in AV access for hemodialysis. V012: prospective randomized blinded trial, target 150 women, 113 enrolled, interim analysis planned on first 80 patients after one year of follow-up. Targeting patients at high risk of fistula failure/non-maturation.
BVP
Preclinical · ActiveModality: regenerative medicine (bioengineered vessel)
Aliases biovascular pancreas
Partnerships Yale University (worldwide patent license, Aug 2019); Breakthrough T1D / JDRF (Industry Discovery and Development Partnership, Apr 2023, for preclinical development and testing)
Indications
type 1 diabetes(Preclinical)
Status note Biovascular pancreas designed to deliver insulin-producing islets using the ATEV as a means of treating type 1 diabetes.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.